Source-grounded facts extracted from Hemab Therapeutics Holdings, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Hemab Therapeutics Holdings, Inc. reported the first quarter ended March 31, 2026 results: net income $22.7 million, or $23.98 per share, EPS $23.98 per share.
“Hemab Therapeutics Holdings, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026.”
Laura Tadvalkar resigned as Director at Hemab Therapeutics Holdings, Inc..
“On May 8, 2026, Laura Tadvalkar, Ph.D., notified Hemab Therapeutics Holdings, Inc. (the “Company”) of her decision to resign as a member of the Company’s board of directors (the “Board”), effective immediately.”
Hemab Therapeutics Holdings, Inc.: Amended and restated bylaws to eliminate stockholder action by written consent, establish procedures for stockholder proposals and director nominations, and conform to the restated certificate (effective 2026-05-04).
“On May 4, 2026, in connection with the closing of the IPO, the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), which were previously approved by the Company’s board of directors and stockholders, became effective upon the closing of the IPO.”
Hemab Therapeutics Holdings, Inc.: Filed a restated certificate of incorporation that increases authorized common stock, eliminates preferred stock references, authorizes undesignated preferred stock, establishes a classified board, modifies director removal and vacancy procedures, eliminates stockholder action by written consent and (effective 2026-05-04).
“On May 4, 2026, Hemab Therapeutics Holdings, Inc. (the “Company”) filed a restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of common stock (the “IPO”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.